You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to www.journalgazette.net/newsletter and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.

Health

  • Virus probed in paralysis cases in 9 Colorado kids
    NEW YORK — Health officials are investigating nine cases of muscle weakness or paralysis in Colorado children and whether the culprit might be a virus causing severe respiratory illness across the country.
  • Study: Blood offers clues to surgery recovery
    One of the big frustrations of surgery: There’s little way to know if you’ll be a fast or slow healer, someone who feels back to normal in a week or is out of work for a month with lingering pain and fatigue.
  • Dengue-blocking mosquito released in Brazil
    Brazilian researchers have freed a batch of mosquitoes infected with a dengue-blocking bacteria they hope can combat the tropical disease naturally.
Advertisement

TB drug put on fast track

J&J earns government’s nod targeting virulent strain

– Johnson & Johnson has won accelerated Food and Drug Administration approval for its tuberculosis tablet Sirturo, the first medicine in 40 years that provides a new way to treat the contagious lung infection.

The FDA cleared Sirturo to be added to existing therapies for use by adults whose illness is resistant to multiple drugs, J&J said Monday in a statement. The FDA cleared Sirturo based on the second of what are typically three clinical trial phases, an option the agency has when a drug treats a serious disease and fills an unmet need.

There were 8.7 million new cases worldwide of tuberculosis in 2011, with multidrug-resistant forms accounting for as many as 400,000 cases, according to a World Health Organization report. The international charity Doctors Without Borders called approval of Sirturo “an immense milestone,” and FDA Commissioner Margaret Hamburg said the drug adds a new weapon “to the arsenal for fighting this deadly, contagious disease.”

“The fact that the drug is active against drug-resistant forms of the disease makes it a potential game changer,” said Dr. Manica Balasegaram, of the Doctors Without Borders Access Campaign.

Most drug-resistant cases occur in China, India, the Russian Federation and South Africa, according to the WHO. While tuberculosis was once the leading cause of death in the U.S., the drug-resistant version of the illness affected about 98 people in the nation last year, according to the Centers for Disease Control and Prevention.

Finding a treatment for tuberculosis was the passion of Paul Janssen, founder of J&J unit Janssen Pharmaceutica, whose sister died of the disease, said Paul Stoffels, J&J’s chief science officer and worldwide chairman of its pharmaceuticals group. U.S. approval will help gain clearance in other countries where the disease is more of a burden, he said.

J&J, based in New Brunswick, N.J., is the parent of Warsaw-based DePuy Synthes Co.

Advertisement